BGNE Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
BeiGene, Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$202.17 |
52 Week High | US$219.64 |
52 Week Low | US$126.97 |
Beta | 0.59 |
11 Month Change | 24.38% |
3 Month Change | 33.64% |
1 Year Change | -5.35% |
33 Year Change | -34.42% |
5 Year Change | 38.91% |
Change since IPO | 613.88% |
Recent News & Updates
BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09Recent updates
BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07Shareholder Returns
BGNE | US Biotechs | US Market | |
---|---|---|---|
7D | 4.1% | 0.4% | 0.6% |
1Y | -5.3% | 14.0% | 22.9% |
Return vs Industry: BGNE underperformed the US Biotechs industry which returned 15.8% over the past year.
Return vs Market: BGNE underperformed the US Market which returned 24.9% over the past year.
Price Volatility
BGNE volatility | |
---|---|
BGNE Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BGNE's share price has been volatile over the past 3 months.
Volatility Over Time: BGNE's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
BGNE fundamental statistics | |
---|---|
Market cap | US$21.14b |
Earnings (TTM) | -US$523.69m |
Revenue (TTM) | US$3.10b |
6.9x
P/S Ratio-41.0x
P/E RatioIs BGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BGNE income statement (TTM) | |
---|---|
Revenue | US$3.10b |
Cost of Revenue | US$465.21m |
Gross Profit | US$2.63b |
Other Expenses | US$3.16b |
Earnings | -US$523.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.94 |
Gross Margin | 84.98% |
Net Profit Margin | -16.91% |
Debt/Equity Ratio | 30.8% |
How did BGNE perform over the long term?
See historical performance and comparison